Alzheimer's Assocation Research only
All of
  • Go to
  • Research Center
  • AAIC
  • Journal
  • Grants
  • TrialMatch
  • Press
  • Donate
  • Contact Us
Science and Progress
Clinical Trials
Funding and Collaboration
You can Help
Stay Current
Video and Resources

Text Size

Small text Medium text Large text

Research Grants 2007

To view an abstract, select an author from the vertical list on the left.

2007 Grant - Van Dyck

Amyloid Binding in Subjects at Risk for Alzheimer's Disease

Christopher Hans Van Dyck, M.D.
Yale University
New Haven, Connecticut

2007 Investigator-Initiated Research Grant

Many factors affect an individual's risk for developing Alzheimer's disease, and inherited genes are one important factor. One of the genes known to be a risk factor for development of the disease is the epsilon 4 variant of the gene APOE. Studies of brain tissue in persons who have died have shown that persons carrying the APOE-e4 gene have greater accumulation of beta-amyloid, a protein fragment that is a primary component of the amyloid plaques seen in the Alzheimer brain.

Recently, new methods have been developed that enable researchers to detect beta-amyloid deposited in the brains of living persons. Christopher van Dyck, M.D.,  and colleagues have proposed using these methods to study the relationship between the APOE-e4 gene and deposition of beta-amyloid in the brains of healthy persons. These studies involve imaging of the brain by positron emission tomography (PET) and the use of a tracer that detects beta-amyloid.

The researchers will study healthy, cognitively normal persons who have a family history of Alzheimer's disease, some of whom also carry the APOE-e4 gene. They will perform imaging studies of the participants' brains to determine if the APOE-e4 gene is associated with earlier or more extensive deposition of beta-amyloid. These studies will test whether the risk of Alzheimer's disease associated with the ApoE-epsilon4 gene can be detected at very early stages. This work could lead to a new diagnostic modality to detect early stages of the disease process before deterioration of brain function can be measured by traditional methods. 

Alzheimer's Association International Conference | July 16-20, 2017, London, England

Abstract Submissions Now Open

The Scientific Program Committee is now accepting submissions for poster
presentations, oral presentations and featured research sessions.